Studies Currently Recruiting |
Name of Study | Study Type | Duration |
ASPREE
Aspirin in Reducing Events in the Elderly | Cardiovascular/Memory / Aspirin | 5 years |
ADNI 2
Alzheimer’s Disease Neuroimaging Initiative 2 | Memory | 4 years |
SPRINT
Systolic Blood Pressure Intervention Trial | Cardiovascular / Blood Pressure Treatment | 5 years |
Ongoing Studies
|
ACCORDION
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-Up Study |
ACCORDION MIND
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-Up Study – Memory in Diabetes Follow-Up Study |
ADNI-GO
Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity (ADNI Go) |
AIM HIGH
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes |
ASPREE HUB
Aspirin in Reducing Events in the Elderly |
BMS
BMSA Multicenter, Randomized Double-Blind Placebo-Controlled Study of the safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease |
DHS MIND
Genetics of Cerebrovascular Disease and Cognitive Impairment in the Diabetes Heart Study |
HBA
Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old |
ICARA
A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non-Carriers (301) or Carriers (302) |
LIFE Cognition
Lifestyle Interventions and Independence for Elders Cognitive Sub Study |
Look AHEAD Ancillary Study
Ancillary Study Intentional Weight Reduction and Physical and Cognitive Function |
S-CONNECT
A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer’s Disease using Alzheimer’s Disease Medication |
SPRINT MIND
The SPRINT Memory and Cognitive IN Decreased hypertension |
Completed Studies
|
ACCORD
Action to Control Cardiovascular Risk in Diabetes |
ACCORD MIND
Action to Control Cardiovascular Risk in Diabetes – Memory in Diabetes |
ADNI
Alzheimer's Disease Neuroimaging Initiative |
DHA
A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease |
GEM
Ginkgo Evaluation of Memory |
IDENTITY
Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo |